 Tiziana Life Sciences Ltd NASDAQ:TLSA has announced the start of enrollment of the first patient cohort in its intermediate-size patient population expanded access program to evaluate foralumab in non-active Secondary Progressive Multiple Sclerosis SPMS patients. This treatment program will evaluate dosing at the standard dosing of 50 mcg and, if needed, a higher 100 mcg dose of intranasal foralumab in two separate cohorts of four non-active SPMS patients each, Tiziana said. 